ON ONCODESIGN Stock: price and management transactions · France · AMFSource id RS00005723 ISIN ISIN FR0011766229FR · AMF Mcap €6.1M 医疗与制药 Follow the ONCODESIGN share price and the full insider trade history of the company, a listed equity based in France. Shares are quoted on the FR market, under the authority of AMF. Operating in the Healthcare & Pharma sector, ONCODESIGN has published 24 insider filings. Market capitalisation: €6.1m. The latest transaction was filed on 16 December 2022 (Acquisition). Among the most active insiders: KARINE LIGNEL. All data is free.
Fundamental score
Ranked 84 of 29,064 companies
FCF yld ·
Earn yld 89%
EV/EBITDA 2.1x
ROE 204%
Gross mgn ·
Net mgn ·
Debt/EBITDA 1.0x
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 December 2022
All Executives24 Thresholds0 Prospectus0 Other0
Declarations 24 total
▲ Chief Executive Officer · Executives · 14 Dec 2022
18,480 shares @ €10.00 48.0% of flow Action ISIN ISIN FR00117662292022DD876483 Canonical exit: 14 Mar 2023 (T+90) ▼ Directrice juridique · Executives · 18 Oct 2022
15,120 shares @ €14.42 100.0% of flow Action ISIN ISIN FR00117662292022DD867535 ▼ DRH membre du comex · Executives · 18 Oct 2022
18,140 shares @ €14.42 72.2% of flow Action ISIN ISIN FR00117662292022DD867537 ● Chief Executive Officer · Executives · 18 Oct 2022
13,860 shares @ €14.42 52.0% of flow Action ISIN ISIN FR00117662292022DD867539 ▼ Directeur administratif et financier - membre du comex · Executives · 18 Oct 2022
21,230 shares @ €14.42 100.0% of flow Action ISIN ISIN FR00117662292022DD867544 ▼ CIO - Directeur BU IA - Membre du comex · Executives · 18 Oct 2022
17,640 shares @ €14.42 100.0% of flow Action ISIN ISIN FR00117662292022DD867548 ▼ Chief Executive Officer · Executives · 18 Oct 2022
220 shares @ €14.42 0.0% of flow Action ISIN ISIN FR00117662292022DD867437 ▼ PRESIDENT DIRECTEUR GENERAL · Executives · 18 Oct 2022
200 shares @ €14.42 0.0% of flow Action ISIN ISIN FR00117662292022DD867438 ▼ PRESIDENT DIRECTEUR GENERAL · Executives · 18 Oct 2022
2,907,258 shares @ €14.42 100.0% of flow Action ISIN ISIN FR00117662292022DD867439 ▼ Deputy CEO · Executives · 18 Oct 2022
357,840 shares @ €14.42 100.0% of flow Action ISIN ISIN FR00117662292022DD867440 ▼ Directrice générale déléguée · Executives · 18 Oct 2022
27,720 shares @ €14.42 42.6% of flow Action ISIN ISIN FR00117662292022DD867441 ▲ AI Business Unit Director & CIO · Executives · 7 Oct 2022
10,080 shares @ €10.00 50.0% of flow Action ISIN ISIN FR00117662292022DD865664 Canonical exit: 5 Jan 2023 (T+90) ▲ Group Chief Financial Officer · Executives · 7 Oct 2022
12,120 shares @ €10.00 50.0% of flow Action ISIN ISIN FR00117662292022DD865665 Canonical exit: 5 Jan 2023 (T+90) ▲ Executive Senior Vice President - Group Chief Development Officer · Executives · 7 Oct 2022
18,480 shares @ €10.00 19.7% of flow Action ISIN ISIN FR00117662292022DD865669 Canonical exit: 5 Jan 2023 (T+90) ▲ Directrice Juridique · Executives · 7 Oct 2022
10,080 shares @ €10.00 34.3% of flow Action ISIN ISIN FR00117662292022DD865671 Canonical exit: 5 Jan 2023 (T+90) ▲ AI Business Unit Director & CIO · Executives · 7 Oct 2022
10,080 shares @ €10.00 50.0% of flow Action ISIN ISIN FR00117662292022DD866011 Canonical exit: 5 Jan 2023 (T+90) ▲ Group Chief Financial Officer · Executives · 7 Oct 2022
12,120 shares @ €10.00 50.0% of flow Action ISIN ISIN FR00117662292022DD866013 Canonical exit: 5 Jan 2023 (T+90) ▲ Executive Senior Vice President - Group Chief Development Officer · Executives · 7 Oct 2022
18,480 shares @ €10.00 19.7% of flow Action ISIN ISIN FR00117662292022DD866014 Canonical exit: 5 Jan 2023 (T+90) ▲ Directrice Juridique · Executives · 7 Oct 2022
10,080 shares @ €10.00 34.3% of flow Action ISIN ISIN FR00117662292022DD866015 Canonical exit: 5 Jan 2023 (T+90) ▲ Chief Human Resources Officer · Executives · 7 Oct 2022
10,080 shares @ €10.00 27.8% of flow Action ISIN ISIN FR00117662292022DD865660 Canonical exit: 5 Jan 2023 (T+90) ▲ Directrice Générale Développement Groupe · Executives · 28 Apr 2022
9,240 shares @ €9.1348 9.0% of flow Action ISIN ISIN FR00117662292022DD839952 Canonical exit: 27 Jul 2022 (T+90) ▲ Directrice Juridique · Executives · 28 Apr 2022
5,040 shares @ €9.1348 15.7% of flow Action ISIN ISIN FR00117662292022DD839975 Canonical exit: 27 Jul 2022 (T+90) ▲ Directrice Générale Développement Groupe · Executives · 28 Apr 2022
9,240 shares @ €9.1348 9.0% of flow Action ISIN ISIN FR00117662292022DD841853 Canonical exit: 27 Jul 2022 (T+90) ▲ Directrice Juridique · Executives · 28 Apr 2022
5,040 shares @ €9.1348 15.7% of flow Action ISIN ISIN FR00117662292022DD841856 Canonical exit: 27 Jul 2022 (T+90) 关于 ONCODESIGN ONCODESIGN 现已成为药物发现和精准医疗领域的知名参与者，最初由 Philippe Genne 于 1995 年在第戎创立。该公司最初是一家药理学服务企业，并逐步建立了一个集成的科学平台，涵盖靶点识别、候选药物筛选和转化研究，并长期专注于肿瘤学。多年来，该集团结合了两项互补业务：为制药和生物技术客户提供研究服务，以及专有的生物技术管线。2022 年 7 月，该集团宣布将这两条业务线分离，创建了 Oncodesign Precision Medicine (OPM) 负责生物技术/人工智能活动，同时将服务业务保留在 Oncodesign Services 之下。
从商业模式的角度来看，Oncodesign Services 作为一家合同研究组织运营，专门从事药物发现和临床前研究。其服务范围涵盖药物化学、体外生物学、药代动力学、生物分析和体内药理学。该公司定位于未满足需求高的治疗领域，特别是肿瘤学，但也包括炎症和传染病。其价值主张建立在强大的科学整合以及与制药公司、生物技术公司、学术机构和公共研究组织的密切合作之上。同时，OPM 开发专有治疗资产，专注于耐药和转移性癌症，利用精准医疗和人工智能能力。
该集团受益于在欧洲生命科学生态系统中的既定认可。其在第戎的历史基地提供了进入坚实的医院-大学环境的途径，而其发展足迹还包括大巴黎地区的其他地点和国际联系。最近的公开披露强调了持续的合作和开发活动，包括肿瘤学、神经病学和炎症性疾病项目。一个值得注意的里程碑是 Oncodesign Services 在 2024 年收购了 ZoBio，这增强了公司在小分子发现和转化研究方面的能力。总的来说，ONCODESIGN 是一家高度专业化、技术驱动的公司，在医疗保健和制药价值链的一个利基但具有战略重要性的领域运营。